ArticleFrontiers in oncology2025
Liver cancer burden attributable to high body mass index and high fasting plasma glucose in BRICS countries (1990-2021): a Global Burden of Disease 2021 analysis with projections to 2050.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: With the escalating prevalence of obesity and diabetes, high body mass index (BMI) and high fasting plasma glucose (HFPG) have emerged as increasingly significant risk factors for liver cancer worldwide. This study evaluates the burden of liver cancer attributable to high BMI and HFPG in BRICS countries from 1990 to 2021 and projects future trends to 2050, drawing upon data from the Global Burden of Disease (GBD) Study 2021. Method: Data on liver cancer burden, stratified by sex and age, were retrieved from the GBD database. Trends were assessed using estimated annual percentage change (EAPC) with 95% confidence intervals. Autoregressive integrated moving average (ARIMA) and exponential smoothing (ES) models were employed to generate future projections. Result: In 2021, South Africa exhibited the highest liver cancer mortality rate attributable to high BMI, whereas India recorded the most rapid growth. Between 1990 to 2021, mortality and disability-adjusted life years (DALYs) associated with high BMI-related liver cancer increased substantially in China, particularly among older populations. The decomposition analysis revealed that epidemiological change was the dominant driver behind the rising burden in both China and India, with population growth being a secondary yet substantial factor. Epidemiological transitions accounted for the predominant rise in mortality and DALYs in China and India. Forecasts indicate persistent increases in liver cancer mortality and DALYs attributable to high BMI and HFPG through 2050. Conclusion: The liver cancer burden attributable to high BMI and HFPG is anticipated to escalate across BRICS countries. Enhanced efforts in prevention, early screening, and comprehensive management of obesity, diabetes, and metabolic disorders are indispensable to mitigate the projected impact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.